Patent classifications
C07C217/78
METHOD OF TREATING CANCER USING SELECTIVE ESTROGEN RECEPTOR MODULATORS
Disclosed herein are methods of treating subjects suffering from estrogen receptor positive cancer of the brain by administering a selective estrogen receptor degrader (SERM). Also disclosed are methods of treating a cancer that is resistant to an estrogen receptor modulator by administering a SERM.
METHOD OF TREATING CANCER USING SELECTIVE ESTROGEN RECEPTOR MODULATORS
Disclosed herein are methods of treating subjects suffering from estrogen receptor positive cancer of the brain by administering a selective estrogen receptor degrader (SERM). Also disclosed are methods of treating a cancer that is resistant to an estrogen receptor modulator by administering a SERM.
Method of treating cancer using selective estrogen receptor modulators
Disclosed herein are methods of treating subjects suffering from estrogen receptor positive cancer of the brain by administering a selective estrogen receptor degrader (SERM). Also disclosed are methods of treating a cancer that is resistant to an estrogen receptor modulator by administering a SERM.
Method of treating cancer using selective estrogen receptor modulators
Disclosed herein are methods of treating subjects suffering from estrogen receptor positive cancer of the brain by administering a selective estrogen receptor degrader (SERM). Also disclosed are methods of treating a cancer that is resistant to an estrogen receptor modulator by administering a SERM.
In-Situ crosslinking of 9,9' -spirobifluorene-based compounds for use in optoelectronic and/or in photoelectrochemical devices and manufacture thereof
The 9,9-spirobifluorene-based compounds and mixtures including 9,9-spirobifluorene compounds with crosslinkable functional groups and compounds with two or more thiol groups, can stabilize one or more underlying layers of the hole transporting layer and/or interlayer during liquid fabrication process of optoelectronic and/or photoelectrochemical devices. More particularly, the compounds are hole transport materials that include crosslinkable functional groups covalently bonded to 9,9-spirobifluorene hole transporting structure and mixtures including hole transporting crosslinkable 9,9-spirobifluorene and thiol derivatives, which may crosslink, such as by exposure to UV, visible light, and/or heat. Photovoltaic devices may employ these compounds and mixtures in crosslinked forms.
In-Situ crosslinking of 9,9' -spirobifluorene-based compounds for use in optoelectronic and/or in photoelectrochemical devices and manufacture thereof
The 9,9-spirobifluorene-based compounds and mixtures including 9,9-spirobifluorene compounds with crosslinkable functional groups and compounds with two or more thiol groups, can stabilize one or more underlying layers of the hole transporting layer and/or interlayer during liquid fabrication process of optoelectronic and/or photoelectrochemical devices. More particularly, the compounds are hole transport materials that include crosslinkable functional groups covalently bonded to 9,9-spirobifluorene hole transporting structure and mixtures including hole transporting crosslinkable 9,9-spirobifluorene and thiol derivatives, which may crosslink, such as by exposure to UV, visible light, and/or heat. Photovoltaic devices may employ these compounds and mixtures in crosslinked forms.
METHOD OF TREATING CANCER USING SELECTIVE ESTROGEN RECEPTOR MODULATORS
Disclosed herein are methods of treating subjects suffering from estrogen receptor positive cancer of the brain by administering a selective estrogen receptor degrader (SERM). Also disclosed are methods of treating a cancer that is resistant to an estrogen receptor modulator by administering a SERM.
Method of treating cancer using selective estrogen receptor modulators
Disclosed herein are methods of treating subjects suffering from estrogen receptor positive cancer of the brain by administering a selective estrogen receptor degrader (SERM). Also disclosed are methods of treating a cancer that is resistant to an estrogen receptor modulator by administering a SERM.
Method of treating cancer using selective estrogen receptor modulators
Disclosed herein are methods of treating subjects suffering from estrogen receptor positive cancer of the brain by administering a selective estrogen receptor degrader (SERM). Also disclosed are methods of treating a cancer that is resistant to an estrogen receptor modulator by administering a SERM.
PHOTOCHROMIC COMPOUND, NAPHTHOL DERIVATIVE, CURABLE COMPOSITION, OPTICAL ARTICLE, LENS, AND EYEGLASSES
The purpose of the present invention is to provide: a photochromic compound having an excellent color fading rate and excellent durability; a naphthol derivative that can become an intermediate for the photochromic compound; and a curable composition, an optical article, a lens and eyeglasses each containing the photochromic compound. According to embodiments, a photochromic compound having a backbone represented by formula (1) is provided. In formula (1), M represents C, Si or Ge; R.sup.1 represents a haloalkyl group having 1 to 20 carbon atoms inclusive; R.sup.2 represents a substituted or unsubstituted alkyl group having 1 to 20 carbon atoms inclusive or a substituted or unsubstituted haloalkyl group having 1 to 20 carbon atoms inclusive.